AAV RS1

Drug Profile

AAV RS1

Alternative Names: adeno-associated viral vector expressing human retinoschisin-1 gene therapy; rAAV hRS1; rAAV2tYF CB hRS1; RS1 AAV vector; XLRS gene therapy

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action RS1 gene expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinoschisis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinoschisis

Most Recent Events

  • 10 Jun 2016 Phase-II clinical trials in Retinoschisis in USA (Intravitreous)
  • 30 Sep 2015 Interim pharmacodynamics and adverse events data from preclinical studies in X-linked retinoschisis released by AGTC
  • 03 Jul 2015 Biogen in-licenses XLRS programme from Applied Genetic Technologies Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top